Abstract
Extensive randomised clinical trial (datasupportthe view that β-blockers have a significant impact opífdíQpd s of patients with cardiovascular disease, especially those with coronary artery isease and chronic heart failure. Unfortunatdje is essential treatment is often withheld from patients with asthma and from som patients with Chronic Obstructive Pulmonary Disease (COPD). The principal concern, concern supported by a number of guidelines, is that β-blockers may pcipitate a vere and potentially fatal bronchospasm. However, a number YXxäre ies, culminating in a recent meta-analysis, show that cardioselective β-blockers are not only safe but are beneficial in patients with co-existing airways and coronary disease. In this article we review the evidence supporting the position that cardioselective β-blockers, when introduced with care in both community and hospital settings, are safe in patients with mild airways disease and can significantly improve prognosis.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ashrafian, H., Violaris, A. Beta-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: The pro viewpoint. Prim Care Respir J 14, 236–241 (2005). https://doi.org/10.1016/j.pcrj.2005.06.005
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1016/j.pcrj.2005.06.005
This article is cited by
-
Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction
Current Heart Failure Reports (2016)